Boston's Office Market Faces Its Toughest Year Since the Pandemic Emptied the Streets

Boston's commercial property market is grinding through what brokers and analysts privately describe as the hardest stretch since 2020. Office vacancy across the metro area hit 18.4 percent in the second quarter of 2026, according to data tracked by Colliers International's Boston office — a figure that would have been unthinkable before the pandemic and that now sits stubbornly near its all-time high. Landlords who once commanded $90-per-square-foot rents in the Seaport District are signing deals at $72 or less, when they can sign deals at all.

The timing matters. Boston's commercial sector had been counting on a full corporate return-to-office cycle by mid-decade. That bet has not paid off. Hybrid work schedules have calcified into permanent policy at dozens of major employers, and the wave of life-sciences leasing that supercharged East Cambridge and the Seaport through 2022 and early 2023 has retreated sharply. Biotech funding dried up faster than anyone predicted, leaving half-finished lab conversions and nervous developers staring at cost overruns.

Two corridors tell the story clearly. Along Northern Avenue in the Seaport, at least four blocks of Class A office space that was fully leased three years ago now carries substantial availability. The Ora building, developed by Skanska USA, has been marketing floors aggressively since early 2025. Meanwhile, on Summer Street near South Station, sublease listings have multiplied — tenants who locked in long-term leases before 2022 are now dumping space at discounts of 30 to 40 percent below direct asking rents. Back Bay fares somewhat better, with Boylston Street and Newbury Street-adjacent offices holding vacancy closer to 13 percent, but even that neighborhood is softer than landlords anticipated heading into this year.

Lab Space Glut Adds Pressure

The life-sciences overhang deserves its own reckoning. Greater Boston added roughly 12 million square feet of lab and lab-conversion space between 2020 and 2025, according to CBRE's New England research team. Demand has not kept pace. In Kendall Square, where Alexandria Real Estate Equities controls several major campuses, asking rents for wet lab space have slipped from a peak of around $130 per square foot annually to somewhere in the $105-to-$115 range, depending on fit-out and lease term. Several smaller biotech firms that had signed letters of intent for Cambridge space in 2023 quietly walked away, forfeiting deposits rather than committing to square footage they could not fill with headcount.

The macroeconomic backdrop is not helping. Global uncertainty — geopolitical volatility across Europe, supply chain reconfiguration, and persistent questions about federal research funding flowing through institutions like Harvard and MIT — has made corporate real estate directors cautious. Companies are extending short-term renewals rather than signing new 10-year leases. That behavior compresses the pipeline of committed deals that brokers rely on to justify new construction starts.

What Landlords and Tenants Are Doing Now

The response from ownership groups has been varied. Granite Properties and certain Boston-based family offices have begun converting underperforming office floors to mixed-use residential in neighborhoods where zoning allows it, particularly around the South End and lower Roxbury corridors where the city has fast-tracked some permitting under its 2024 housing action plan. It is slow, expensive work — conversion costs routinely run $300 to $400 per square foot — but landlords see no better alternative for buildings that cannot compete on amenities.

Tenants, for their part, have significant leverage for the first time in a decade. Companies renegotiating leases this year are extracting meaningful concessions: free-rent periods of six to twelve months, generous tenant improvement allowances, and rights to contract space if headcount falls. The power has shifted.

Brokers expect vacancy to remain elevated at least through the first half of 2027, absent a significant rebound in life-sciences venture funding or a decisive shift in how Boston's large financial and professional services firms manage their footprints. The Federal Reserve's rate path will matter enormously — cheaper debt makes conversion projects and new development pencil out more easily. Until that clarity arrives, the office market's recovery is measured in years, not quarters.